309 related articles for article (PubMed ID: 3997282)
1. Immunogenicity of melanoma-associated gangliosides in cancer patients.
Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL
Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282
[TBL] [Abstract][Full Text] [Related]
2. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
3. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
[TBL] [Abstract][Full Text] [Related]
4. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.
Livingston PO; Ritter G; Calves MJ
Cancer Immunol Immunother; 1989; 29(3):179-84. PubMed ID: 2731184
[TBL] [Abstract][Full Text] [Related]
5. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.
Takahashi T; Johnson TD; Nishinaka Y; Morton DL; Irie RF
J Invest Dermatol; 1999 Feb; 112(2):205-9. PubMed ID: 9989797
[TBL] [Abstract][Full Text] [Related]
6. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
[TBL] [Abstract][Full Text] [Related]
7. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
Livingston PO
Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
[TBL] [Abstract][Full Text] [Related]
8. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications.
Perez CA; Ravindranath MH; Soh D; Gonzales A; Ye W; Morton DL
Cancer J; 2002; 8(5):384-94. PubMed ID: 12416896
[TBL] [Abstract][Full Text] [Related]
9. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
[TBL] [Abstract][Full Text] [Related]
10. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
[TBL] [Abstract][Full Text] [Related]
11. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
12. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. EORTC Cooperative Melanoma Group.
Portoukalian J; Carrel S; Doré JF; Rümke P
Int J Cancer; 1991 Dec; 49(6):893-9. PubMed ID: 1959994
[TBL] [Abstract][Full Text] [Related]
14. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy.
Ravindranath MH; Morton DL; Irie RF
Cancer Res; 1989 Jul; 49(14):3891-7. PubMed ID: 2472199
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma.
Ritter G; Ritter-Boosfeld E; Adluri R; Calves M; Ren S; Yu RK; Oettgen HF; Old LJ; Livingston PO
Int J Cancer; 1995 Sep; 62(6):668-72. PubMed ID: 7558412
[TBL] [Abstract][Full Text] [Related]
16. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
17. Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.
Abdel-Wahab Z; Li WP; Darrow T; Nudelman ED; Towell A; Seigler HF
Melanoma Res; 1993 Dec; 3(6):415-23. PubMed ID: 8161881
[TBL] [Abstract][Full Text] [Related]
18. Attachment of monophosphoryl lipid A (MPL) to cells and liposomes augments antibody response to membrane-bound gangliosides.
Ravindranath MH; Morton DL; Irie RF
J Autoimmun; 1994 Dec; 7(6):803-16. PubMed ID: 7888037
[TBL] [Abstract][Full Text] [Related]
19. Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma.
Hersey P
Cancer Treat Res; 1991; 54():137-51. PubMed ID: 1673856
[TBL] [Abstract][Full Text] [Related]
20. Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2.
Hoon DS; Irie RF; Cochran AJ
Cell Immunol; 1988 Feb; 111(2):410-9. PubMed ID: 3123073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
